Company / Cash & Equivalents
PULSE BIOSCIENCES, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$80.7M
FY2025
5-year range
$28.6M / $118.0M
FY2021-FY2025
Trend
-31.6%
vs FY2024
Sector context
#118 of 148
Health Care
What the data says
PULSE BIOSCIENCES, INC.'s cash & equivalents of $81M is lower than 80% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $2M in FY2016 to $118M in FY2024.
Based on SEC 10-K filings.
$81M in FY2025 with a 5-year CAGR of +45.3%.
Improved from $44M to $81M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +9.7%
- 5-Year CAGR
- +45.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 148This company $80.7M Sector average $1.2B
▼
-93.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +45.3%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 31.6% year-over-year.
- Ranks #118 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $80.7M | -31.6% |
| FY2024 | $118.0M | +166.1% |
| FY2023 | $44.4M | -27.4% |
| FY2022 | $61.1M | +113.7% |
| FY2021 | $28.6M | +129.6% |
| FY2020 | $12.5M | +80.6% |
| FY2019 | $6.9M | -86.5% |
| FY2018 | $51.1M | +1409.2% |
| FY2017 | $3.4M | +62.1% |
| FY2016 | $2.1M | -42.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026